CASP3 and myeloid sarcoma: Caspase inhibition is therapeutically indicated in AD, MS, and other HNDDs. Since caspase-3 promotes pyroptosis (apoptosis associated with a high inflammatory component), suppressing pyroptosis becomes a promising strategy in the management of MS.